Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Related Articles
Commentaries
MAKE A COMMENT
All fields requiredMore Views
- FBI probes racist text message campaign against Black Americans referencing slavery
- Cuba remains vigilant in the face of measles cases in the Americas.
- Alfredo Jalife analyzes the implications of Trump's return for Latin America
- World Conference Against Hunger calls for cooperation in the Face of Challenges
- Brazil shows good pace in job creation